Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced positive headline results from the Phase III STEP UP study, assessing the efficacy and safety of subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo. The study met its primary endpoint, demonstrating superior weight loss outcomes with the higher dose.
Study Results
Specifically, participants treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks, compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. Additionally, 33.2% of those who received semaglutide 7.2 mg achieved a weight loss of 25% or more after 72 weeks, compared to 16.7% with semaglutide 2.4 mg and 0.0% with placebo. The higher dose of semaglutide also showed a good safety and tolerability profile.
Semaglutide: GLP-1 Analogue for T2D and Obesity
Semaglutide is an oral glucagon-like peptide-1 (GLP-1) analogue used for the treatment of type 2 diabetes (T2D) and obesity under the trade names Ozempic and Wegovy, respectively. The approved weight loss version currently comes in a dose of 2.4 mg. The results of the Phase III STEP UP T2D study for semaglutide 7.2 mg in T2D and obesity are expected to read out in the next couple of months, further validating the potential of this higher dose in clinical practice.-Fineline Info & Tech
